Kansas City, Mo.-based healthcare provider Cerner (NSDQ:CERN) received FDA clearance to market its mobile maternal and fetal monitoring system, called Cerner FetaLink+, a device that help clinicians monitor mothers and babies using iPads or iPhones.
The newly approved Cerner FetaLink+, which integrates with Cerner’s PowerChart Touch iPad app, provides near real-time access to critical information about the status of patients and waveform data over time, according to the press release.
The system could also create lifetime electronic health records for mothers and babies, the company said.
Clinicians can quickly view annotations summaries in chronological order on the fetal strip and analyze each data independently or collectively to better make decisions, Cerner said.
Cerner earlier this month acquired Arizona-based Anasazi Software, a behavioral healthcare technology provider, forming the combined Cerner Millennium, which allows behavioral health providers access to data in hopes of coordinating care across the healthcare continuum.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.